Clinical Trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Protocol Amendment History 2 changes
notable Trial sites expanded: 346 -> 351 locations 2026-04-28
notable Trial sites expanded: 337 -> 346 locations 2026-04-08
Trial Details
NCT Number NCT06875310
Lead Sponsor Mirati Therapeutics Inc.
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 630 participants
Start Date 2025-04-24
Primary Completion 2029-09-07 (estimated)
Study Completion 2032-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14